BIIB240726C235000
- 1.10
- -1.40-56.00%
Biogen Newsroom
Sage Therapeutics/Biogen's Episodic Therapy Zuranolone Could Change MDD Treatment
Biogen Inc. (NASDAQ:BIIB) Stock Is Going Strong But Fundamentals Look Uncertain: What Lies Ahead ?
Biogen's (NASDAQ:BIIB) stock is up by a considerable 16% over the past three months. However, we wonder if the company's inconsistent financials would have any adverse impact on the current share
Analysts' Opinions Are Mixed on These Healthcare Stocks: Novartis AG (Six Swiss: CH:NOVN), Biogen (BIIB) and Sartorius (GB:0NIR)
Ionis (IONS) Completes Enrolment for Rare Disease Drug Study
Biogen Earnings Preview: What to Expect
Analysts Conflicted on These Healthcare Names: UnitedHealth (UNH) and Biogen (BIIB)
Hold Rating on Biogen Amid Uncertain Sales Projections for Leqembi and Skyclarys
Why Biogen Inc. (BIIB) Is a Top Value Stock for the Long-Term
Wells Fargo Maintains Biogen(BIIB.US) With Hold Rating, Maintains Target Price $240
Wells Fargo analyst Mohit Bansal maintains $Biogen(BIIB.US)$ with a hold rating, and maintains the target price at $240.According to TipRanks data, the analyst has a success rate of 63.9% and a
Friedreich's Ataxia Market to Grow at a Substantial Growth Rate by 2034, Examines DelveInsight | Key Companies - Retrotope, PTC Therapeutics, Minoryx Therapeutics, Biogen, Lexeo Therapeutics, Larimar Therapeutics
New York, USA, July 16, 2024 (GLOBE NEWSWIRE) -- Friedreich's Ataxia Market to Grow at a Substantial Growth Rate by 2034, Examines DelveInsight | Key Companies - Retrotope, PTC Therapeutics, Minoryx
Biogen Needs Revenue-Generating Assets to Complete Turnaround, Wedbush Says
Biogen (BIIB) needs to acquire additional revenue-generating assets for the turnaround to complete, Wedbush said in a Tuesday note to clients.The company has indicated capacity for $8 billion to $10
Viridian, Pharvaris Said to Be Among Prime M&A Targets for Biogen
Biogen's Strategic Acquisitions and Growth Potential: An Analyst's Hold Rating Justification
Goldman Sachs Adjusts Price Target on Biogen to $342 From $340, Maintains Buy Rating
Biogen (BIIB) has an average outperform rating and a price target range of $200 to $350, according to analysts polled by Capital IQ.Price: 222.01, Change: +0.43, Percent Change: +0.19
Jeito Capital Consolidates Its Support in CatalYm With a Renewed Participation in a $150 Million Financing
Jeito Capital consolidates its support in CatalYm with a renewed participation in a $150 million financing
Bernie Sanders: 'Getting Sick In America Should Not Mean Going Bankrupt, Losing Your Home, Car, Or Life Savings'
Sen. Bernie Sanders (I-Vt.) recently expressed his concerns about the high cost of medical care in the United States, highlighting the financial burden it places on patients.
Lexeo Stock Drops 24% Amid Friedreich Ataxia Study Results
Morgan Stanley Sees $180B Patent Cliff, $380B Deal Capacity Fueling Biopharma M&A
Biogen, Eisai Get Approval for Leqembi in Israel for Treatment of Alzheimer's Disease
Biogen (BIIB) and Eisai said Friday that the Leqembi has been approved in Israel for the treatment of patients with Alzheimer's disease.The drug should be initiated in patients with mild cognitive
Biogen Price Target Cut to $313.00/Share From $335.00 by Piper Sandler
Biogen Price Target Cut to $313.00/Share From $335.00 by Piper